# Vectora Inbox â€” LAI Runtime Corrections: RÃ©sumÃ© des Phases 2-3

**Date:** 2025-01-XX  
**Statut:** âœ… PHASES 2-3 IMPLÃ‰MENTÃ‰ES, PRÃŠT POUR PHASE 4  

---

## Vue d'Ensemble

Ce document rÃ©sume les corrections apportÃ©es aux Phases 2 et 3 pour rÃ©soudre les root causes RC2 et RC3 du problÃ¨me de prÃ©cision LAI.

---

## Phase 2 â€” Filtrage des CatÃ©gories

### Objectif
Corriger RC2 : generic_terms et negative_terms non filtrÃ©s

### Modifications

| Fichier | Modification | Impact |
|---------|--------------|--------|
| `matcher.py` | Exclusion de `generic_terms` du comptage | PEG, liposomes ne matchent plus seuls |
| `matcher.py` | Veto `negative_terms` avec early exit | oral tablet, topical rejettent le match |
| `matcher.py` | Logs `[SIGNAL_COUNT]`, `[SIGNAL_SUMMARY]` | TraÃ§abilitÃ© des signaux utilisÃ©s |

### RÃ©sultat Attendu
- âŒ Items avec seulement "PEG" â†’ NO MATCH
- âŒ Items avec "oral tablet" â†’ NO MATCH
- âœ… RÃ©duction des faux positifs

---

## Phase 3 â€” Fallback & Pure_Player

### Objectif
Corriger RC3 : Distinction pure_player/hybrid non exploitÃ©e

### Modifications

| Fichier | Modification | Impact |
|---------|--------------|--------|
| `domain_matching_rules.yaml` | `min_matches: 2` pour technology | Fallback plus strict |
| `matcher.py` | Seuils adaptatifs par company type | Pure players favorisÃ©s |
| `scorer.py` | Fallback amÃ©liorÃ© pour bonus scoring | Bonus appliquÃ© mÃªme sans profile |

### Logique de Matching Adaptative

```
Pure Player (MedinCell, Camurus, etc.):
  âœ… MATCH if high_precision >= 1
  â†’ Seuils relaxÃ©s

Hybrid (Pfizer, Novartis, etc.):
  âœ… MATCH if high_precision >= 1 AND supporting >= 1
  â†’ Seuils stricts

Other:
  âœ… MATCH if high_precision >= 1 AND supporting >= 1
  â†’ Seuils standard
```

### Bonus de Scoring

| Type | Bonus | PrioritÃ© |
|------|-------|----------|
| Pure player | +3 points | Haute |
| Hybrid | +1 point | Moyenne |
| Other | 0 point | Basse |

### RÃ©sultat Attendu
- âœ… Pure players priorisÃ©s (MedinCell, Camurus en tÃªte)
- âŒ Hybrid filtrÃ©s (Pfizer seulement si signaux forts)
- âœ… Pure player % > 30%

---

## Comparaison Avant/AprÃ¨s

### MÃ©triques Cibles

| MÃ©trique | Avant P2-P3 | AprÃ¨s P2-P3 | Objectif MVP |
|----------|-------------|-------------|--------------|
| LAI precision | 0% | â‰¥50% | â‰¥80% |
| Pure player % | 0% | â‰¥30% | â‰¥50% |
| False positives | 2/5 (40%) | <2/5 | 0 |

### Comportement de Matching

| ScÃ©nario | Avant | AprÃ¨s P2 | AprÃ¨s P3 |
|----------|-------|----------|----------|
| MedinCell + "long-acting injection" | âŒ NO MATCH | âœ… MATCH | âœ… MATCH (high score) |
| Pfizer + "PEG" seul | âœ… MATCH (faux positif) | âŒ NO MATCH | âŒ NO MATCH |
| Novartis + "oral tablet" | âœ… MATCH (faux positif) | âŒ NO MATCH (veto) | âŒ NO MATCH (veto) |
| Camurus + "subcutaneous" + "monthly" | âŒ NO MATCH | âœ… MATCH | âœ… MATCH (high score) |
| Pfizer + "LAI" + "depot" | âŒ NO MATCH | âœ… MATCH | âœ… MATCH (medium score) |

---

## Logs de TraÃ§abilitÃ©

### Phase 2 - Filtrage

```
[SIGNAL_COUNT] High precision: core_phrases = 1
[SIGNAL_COUNT] Supporting: route_admin_terms = 1
[SIGNAL_SUMMARY] High precision: 1, Supporting: 1
[SIGNAL_SUMMARY] Categories used: ['core_phrases', 'route_admin_terms']
[NEGATIVE_VETO] Match rejected due to negative terms: ['oral tablet']
```

### Phase 3 - Pure_Player

```
[COMPANY_TYPE] Pure player detected, using relaxed thresholds (HP>=1)
[SCORING] Pure player bonus applied: ['MedinCell']
[SCORING_FALLBACK] Pure player bonus applied: ['Camurus']
```

---

## Fichiers ModifiÃ©s

### Configuration
- âœ… `canonical/matching/domain_matching_rules.yaml`

### Code Runtime
- âœ… `src/vectora_core/matching/matcher.py`
- âœ… `src/vectora_core/scoring/scorer.py`

### Documentation
- âœ… `docs/diagnostics/vectora_inbox_lai_runtime_phase2_filtrage_categories.md`
- âœ… `docs/diagnostics/vectora_inbox_lai_runtime_phase3_fallback_pureplayer.md`
- âœ… `CHANGELOG.md`

### Scripts
- âœ… `scripts/deploy_phase2.ps1`
- âœ… `scripts/deploy_phase3.ps1`

---

## DÃ©ploiement

### Phase 2 Seule
```powershell
.\scripts\deploy_phase2.ps1
```

### Phase 3 Seule
```powershell
.\scripts\deploy_phase3.ps1
```

### Phases 2+3 CombinÃ©es
```powershell
# Upload config
aws s3 cp canonical/matching/domain_matching_rules.yaml s3://vectora-inbox-config-dev/canonical/matching/

# Repackage + deploy
python scripts/package_lambda.py
python scripts/deploy_lambda.py --env dev

# Test
python scripts/run_engine.py --env dev --client lai_weekly
```

---

## Validation

### Commandes de Test

```powershell
# 1. Lancer l'engine
python scripts/run_engine.py --env dev --client lai_weekly

# 2. TÃ©lÃ©charger la newsletter
aws s3 cp s3://vectora-inbox-newsletters-dev/lai_weekly/latest/newsletter.json .

# 3. Analyser les rÃ©sultats
python scripts/analyze_newsletter.py newsletter.json --detailed

# 4. VÃ©rifier les logs Phase 2
aws logs tail /aws/lambda/vectora-inbox-engine-dev --since 1h --filter-pattern "[SIGNAL_SUMMARY]"
aws logs tail /aws/lambda/vectora-inbox-engine-dev --since 1h --filter-pattern "[NEGATIVE_VETO]"

# 5. VÃ©rifier les logs Phase 3
aws logs tail /aws/lambda/vectora-inbox-engine-dev --since 1h --filter-pattern "[COMPANY_TYPE]"
aws logs tail /aws/lambda/vectora-inbox-engine-dev --since 1h --filter-pattern "[SCORING]"
```

### CritÃ¨res de SuccÃ¨s

#### Phase 2
- âœ… generic_terms exclus du comptage
- âœ… negative_terms appliquÃ©s comme veto
- âœ… Logs dÃ©taillÃ©s disponibles
- âœ… RÃ©duction des faux positifs observÃ©e

#### Phase 3
- âœ… Pure players favorisÃ©s (au moins 1 dans les rÃ©sultats)
- âœ… Hybrid filtrÃ©s (moins de faux positifs big pharma)
- âœ… Pure player % > 30%
- âœ… Logs de company type disponibles

---

## Risques & Mitigations

### ðŸŸ¡ Sur-filtrage (Phase 2)
**Risque:** Trop de termes classÃ©s comme generic_terms  
**Mitigation:** VÃ©rifier la configuration des catÃ©gories dans `lai_keywords.yaml`

### ðŸŸ¡ Seuils trop stricts (Phase 3)
**Risque:** Vrais positifs hybrid rejetÃ©s  
**Mitigation:** Analyser les items rejetÃ©s, ajuster `min_supporting` si nÃ©cessaire

### ðŸŸ¢ Pas de risque de rÃ©gression
Les modifications sont isolÃ©es dans la logique de profile matching LAI.

---

## Prochaines Ã‰tapes

### Phase 4 â€” Test End-to-End & MÃ©triques

1. **DÃ©ployer les Phases 2+3**
2. **Lancer un run complet lai_weekly**
3. **Mesurer les mÃ©triques finales:**
   - LAI precision
   - Pure player %
   - False positives
4. **DÃ©cision GO/NO-GO:**
   - ðŸŸ¢ GREEN (GO PROD) : 3/3 objectifs atteints
   - ðŸŸ¡ AMBER (ITERATION) : 2/3 objectifs atteints
   - ðŸ”´ RED (NO-GO) : <2 objectifs atteints

---

## Notes Techniques

### Scopes UtilisÃ©s

**Pure players (19 companies):**
- `lai_companies_pure_players` (14)
- `lai_companies_mvp_core` (5)

**Hybrid (27 companies):**
- `lai_companies_hybrid`

### CatÃ©gories de Signaux

**High precision:**
- `core_phrases` (long-acting injection, depot formulation, etc.)
- `technology_terms_high_precision` (microspheres, PLGA, etc.)

**Supporting:**
- `route_admin_terms` (intramuscular, subcutaneous, etc.)
- `interval_patterns` (monthly, quarterly, etc.)

**Excluded:**
- `generic_terms` (PEG, liposomes, etc.)

**Negative:**
- `negative_terms` (oral tablet, topical, etc.)

---

## RÃ©sumÃ© ExÃ©cutif

### ProblÃ¨mes RÃ©solus
- âœ… RC2 : generic_terms et negative_terms maintenant filtrÃ©s
- âœ… RC3 : Distinction pure_player/hybrid maintenant exploitÃ©e

### AmÃ©liorations ApportÃ©es
- RÃ©duction des faux positifs (filtrage des termes gÃ©nÃ©riques et nÃ©gatifs)
- Priorisation des pure players (seuils adaptatifs + bonus scoring)
- TraÃ§abilitÃ© complÃ¨te (logs dÃ©taillÃ©s Ã  chaque Ã©tape)

### RÃ©sultat Attendu
- LAI precision : 0% â†’ â‰¥50%
- Pure player % : 0% â†’ â‰¥30%
- False positives : 2/5 â†’ <2/5

### Prochaine Ã‰tape
**Phase 4 : Validation end-to-end et dÃ©cision GO/NO-GO**
